Toroso Investments LLC increased the amount of money it had invested in Zimmer Biomet Holdings, INC (NYSE: ZBH) by 16.7% during the third quarter, as stated in the most recent Form 13F filing that the company made with the Securities and Exchange Commission. Following the completion of an additional 4,103 stock purchases during the period in question, the fund ended the period with a total of 28,621 shares of the stock held by the company responsible for supplying medical equipment.
The most recent report that Toroso Investments LLC submitted to the Securities and Exchange Commission indicated that the value of the company’s holding in Zimmer Biomet was $2,992,000.
This information was derived from the filing of that report.
On February 3, the most recent quarterly earnings report for Zimmer Biomet (NYSE: ZBH) was made public for the investing community.
The medical equipment manufacturer reported earnings per share (EPS) for the quarter to be $1.88.
This figure is $0.05 higher than the average estimate of $1.83, which market analysts reported.
The following percentages represent the net margin and return on equity for Zimmer Biomet: 3.33% and 11.97%, respectively.
The company’s revenue came in at $1.83 billion for the quarter, significantly higher than the average prediction of $1.76 billion made by financial analysts.
The company reported earnings of $1.95 per share for the same period the year before when compared to the current year. Compared to the results achieved during the same period in the previous year, the rise in quarterly revenue was 2.7% higher than the prior year’s performance.
Analysts of the stock market forecast that Zimmer Biomet Holdings INC will bring in profits of $7.04 per share during the current fiscal year.
When trading started on Thursday, the price of a share of ZBH stock was 125.26 dollars. Given its current market value of $26.31 billion, its P/E ratio of 113.87, its PEG ratio of 2.85, and its beta value of 1.00, the company has adequate financial resources.
This stock’s simple moving average over the past 50 days comes in at $125.25, and the simple moving average over the past 200 days is $118.45.
The lowest price that Zimmer Biomet Holdings, INC has been at in the past year is $100.39, while the company’s all-time high price is $135.05.
The quick ratio is 0.97, the current ratio is 1.88, and the debt-to-equity ratio is 0.43.
All of these numbers are relative to the total amount of debt.
All these figures should be interpreted in light of the overall sum owed.
There have been transactions involving ZBH shares that several hedge funds have carried out.
In the first three months of this year, Fairfield Bush & Co spent $111,000 to acquire a new position at Zimmer Biomet.
During the first three months of 2018, United Bank increased the percentage of Zimmer Biomet stock owned by 4.1%. Following the purchase of 437 additional shares during the most recent quarter, United Bank now possesses 11,072 shares of the medical equipment provider’s stock, valued at $1,416,000.
This brings the total number of shares owned by United Bank to 11,072.
During the first three months of 2018, Panagora Asset Management INC increased the amount of Zimmer Biomet stock owned by 153.9%, bringing the total amount of Zimmer Biomet stock it owned to 1.
After making a new purchase of 5,942 shares during the most recent fiscal quarter, Panagora Asset Management INC now owns 9,803 shares of the medical equipment provider’s stock, valued at $1,254,000.
This brings the total value of the company’s holdings to $1,254,000.
During the first three months of 2018, Aviva PLC increased the amount of Zimmer Biomet stock owned by 0.4%, bringing its total ownership percentage to 98.6%. Following acquiring an additional 137 shares during the most recent quarter, Aviva PLC now possesses 30,636 shares of the stock held by the medical equipment provider.
The price of one share of stock is currently $3,918,000.
Last but not least, during the first three months of 2018, Allianz Asset Management GmbH added 11.2% more Zimmer Biomet stock to its holdings, bringing the total percentage of the company’s stock it possessed to 88.4%.
Allianz Asset Management GmbH now holds 41,816 shares of the medical equipment provider’s stock, with a market value of $5,348,000 following the acquisition of 4,224 additional shares during the preceding quarter.
The majority of the company’s stock is owned by large financial institutions, which account for 87.21% of the total.
In addition, the business has declared a quarterly dividend, which will be paid out on April 28 as previously scheduled. Shareholders still registered as such as of March 29 will be eligible to receive a $0.24 dividend payment per share. On March 28, shareholders will no longer be eligible to receive dividends.
This equates to an annual dividend payment of 0.96 dollars and a dividend yield of 0.77 percent.
The dividend payout ratio (DPR) for Zimmer Biomet currently stands at 87.27 percent.
In recent press releases, several research analysts were asked about their thoughts on ZBH stock and responded. JMP Securities reaffirmed their “market outperform” rating on shares of Zimmer Biomet and positioned their price objective for the company at $145.00 in a research note that was dated February 7.
In a report distributed on Monday, January 9, Royal Bank of Canada raised their price objective for shares of Zimmer Biomet from $125.00 to $141.00 and upgraded the stock from a “sector perform” rating to an “outperform” rating.
The price objective that Robert W.
Baird has set for Zimmer Biomet has increased from $133.00 to $145.00 due to a research report that was made public on February 6. StockNews.com started reporting on the share price of the company about the Zimmer Biomet brand on Thursday.
They suggested to the investors that the best course of action would be to “buy” the shares.
Piper Jaffray raised their price target for shares of Zimmer Biomet from $135.00 to $145.00 and upgraded the stock from a “neutral” rating to an “overweight” rating in a report published on Thursday, March 9. Seven analysts have issued a recommendation to buy shares of the company, five have issued a recommendation to hold shares, and two market watchers have issued a recommendation to sell shares.
The current recommendation for Zimmer Biomet is “Hold,” and the consensus price objective for the company is set at $133.56, according to the data provided by Bloomberg.